ABSTRACT
Presently, there is a huge hype and excitement in the field of synthetic biologics and engineering regarding growing cases of their implication in various fields including health care systems. Furthermore, despite its large body of suggestive and fascinating accomplishments, the synthetic area is always been subject of much more prejudice and debate. However, over a couple of years, the generation of researchers had tested one of such disease modifying compound Pirfenidone (Esbriet®), to unleash their potential in the different disciplines of interventional pharmacology and therapy. In this pipeline, depending on its success of multiple missions, in context to advancing the therapy for different diseases, it became the first prescribed medicine to treat the people with one characteristic lung disorder called idiopathic pulmonary fibrosis (IPF). This review discusses the different therapeutic strategies beyond its well-known anti-fibrotic activity in several well-characterized animals, cell-based and human models and also regarding facts of Pirfenidone (PFD) as anti-inflammatory, anti-fibrinogenic, anti-oxidants including in the treatment of diabetic neuropathy, liver cirrhosis etc. This review also contains current investigations, focusing mainly on the novel findings and their outcomes in improving the quality of life of patients with different conditions and also suggests their implication on the basis of fundamental existential evidences to break the major impediment in transforming this disease-modifying drug into a personalized medicine.
ABSTRACT
Aims: The present work was decided to evaluate the in-vitro anti-inflammatory activity of crude extracts of Bombax ceiba in order to characterize the role of this extract in affecting the inflammatory process. Study Design: Extraction of B. ceiba bark, phytochemical screening, and evaluation of invitro anti-inflammatory activity. Methodology: Petroleum ether, ethanol and aqueous extracts of B. ceiba barks were prepared by maceration technique and subjected to preliminary phytochemical tests. The in-vitro anti-inflammatory activity of all extracts (1000 mcg/ml) was assessed by HRBC membrane stabilization method. Results: Ethanol extract showed significant (p<0.001) response followed by aqueous extract (p<0.01) when compared with standard, diclofenac potassium (50 mcg/ml). Conclusion: The study suggests that the extracts possess enough potential to reduce inflammation by in-vitro and directs the importance of further research and development of novel anti-inflammatory agents.
ABSTRACT
A series of several novel mannich bases of indoles (1A-L) have been synthesized from indole by reacting with respective aldehyde and the various compounds containing secondary amine. The synthesized compounds were characterized by IR and 1HNMR spectral analysis. All the synthesized compounds were evaluated for their anti-nociceptive activity in mice by Eddy’s hot plate method. The reaction time was compared with standard drug pentazocine. In vitro antimicrobial activity of the synthesized compounds were screened against the Gram positive microorganisms such as Staphylococcus aureus, Streptococcus pyogenes, Gram negative microorganisms such as Escherchia coli, Klebsiella aerogenes and fungus Candida albicans by cup plate method. The zone of inhibition of the synthesized compounds was compared with the standard drug amikacin and ketoconazole respectively. All the synthesized compounds exhibited significant anti-nociceptive activity and showed moderate antimicrobial activity.